Abstract
Non-opioid analgesics including both selective and non-selective cyclooxygenase (COX) inhibitors and acetaminophen are the most widely used treatments for pain. Inhibition of COX is thought to be largely responsible for both the therapeutic and adverse effects of this class of drugs. Accumulating evidence over the past two decades has demonstrated effects of non-opioids beyond the inhibition of COX and prostaglandin synthesis that might also explain their therapeutic and adverse effects. These include their interaction with endocannabinoids, nitric oxide, monoaminergic, and cholinergic systems. Moreover, the recent development of microarray technology that allows the study of human gene expression suggests multiple pathways that may be related to the analgesic and anti-inflammatory effects of non-opioids. The present review will discuss the multiple actions of non-opioids and their interactions with these systems during inflammation and pain, suggesting that COX inhibition is an incomplete explanation for the actions of non-opioids and proposes the involvement of multiple selective targets for their analgesic, as well as, their adverse effects.
Keywords: NSAIDs, endocannabinoids, monoaminergic systems, cholinergic system, nitric oxide, interleukin-6, matrix metalloproteinases, inflammatory pain
Current Molecular Pharmacology
Title: Mechanisms of Non-Opioid Analgesics Beyond Cyclooxygenase Enzyme Inhibition
Volume: 2
Author(s): May Hamza and Raymond A. Dionne
Affiliation:
Keywords: NSAIDs, endocannabinoids, monoaminergic systems, cholinergic system, nitric oxide, interleukin-6, matrix metalloproteinases, inflammatory pain
Abstract: Non-opioid analgesics including both selective and non-selective cyclooxygenase (COX) inhibitors and acetaminophen are the most widely used treatments for pain. Inhibition of COX is thought to be largely responsible for both the therapeutic and adverse effects of this class of drugs. Accumulating evidence over the past two decades has demonstrated effects of non-opioids beyond the inhibition of COX and prostaglandin synthesis that might also explain their therapeutic and adverse effects. These include their interaction with endocannabinoids, nitric oxide, monoaminergic, and cholinergic systems. Moreover, the recent development of microarray technology that allows the study of human gene expression suggests multiple pathways that may be related to the analgesic and anti-inflammatory effects of non-opioids. The present review will discuss the multiple actions of non-opioids and their interactions with these systems during inflammation and pain, suggesting that COX inhibition is an incomplete explanation for the actions of non-opioids and proposes the involvement of multiple selective targets for their analgesic, as well as, their adverse effects.
Export Options
About this article
Cite this article as:
Hamza May and Dionne A. Raymond, Mechanisms of Non-Opioid Analgesics Beyond Cyclooxygenase Enzyme Inhibition, Current Molecular Pharmacology 2009; 2 (1) . https://dx.doi.org/10.2174/1874467210902010001
DOI https://dx.doi.org/10.2174/1874467210902010001 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reversal of Multidrug Resistance by Natural Substances from Plants
Current Topics in Medicinal Chemistry Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery Syntheses, Transformations and Pharmaceutical Applications of Kynurenic Acid Derivatives
Current Medicinal Chemistry Patent Selections
Recent Patents on Food, Nutrition & Agriculture A Dual Mechanism Linking NGF/proNGF Imbalance and Early Inflammation to Alzheimer's Disease Neurodegeneration in the AD11 Anti-NGF Mouse Model
CNS & Neurological Disorders - Drug Targets Antisense Oligonucleotides for the Treatment of Dyslipidemia
Current Pharmaceutical Design Acridones As Antiviral Agents: Synthesis, Chemical and Biological Properties
Current Medicinal Chemistry MIF and the Genetic Basis of Macrophage Responsiveness
Current Immunology Reviews (Discontinued) Biological Activities of Yarrow Species (Achillea spp.)
Current Pharmaceutical Design Neuroinflammation, Oxidative Stress and the Pathogenesis of Alzheimers Disease
Current Pharmaceutical Design Histone Deacetylase Inhibitors: Novel Immunomodulators
Current Enzyme Inhibition Impaired Clearance of Neutrophils Extracellular Trap (NET) May Induce Detrimental Tissular Effect
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus
Current Pharmaceutical Design ACE and ACE2 in Inflammation: A Tale of Two Enzymes
Inflammation & Allergy - Drug Targets (Discontinued) Nano-Lipid-Carriers for the Treatment of Vitiligo: A Recent Update, Pathophysiology and Mechanism of Drug Delivery
Current Molecular Pharmacology Editorial [Hot Topic: Current Strategies in Vascular Biology (Guest Editor: Elisabeth Deindl)]
Current Pharmaceutical Biotechnology Targeting βIII-Tubulin in Glioblastoma Multiforme: From Cell Biology and Histopathology to Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Functional Renal MRI
Current Medical Imaging The Molecular Basis of Herpesviruses as Oncolytic Agents
Current Pharmaceutical Biotechnology